Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RhoC siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
RhoC siRNA is a small interfering RNA designed to silence the expression of the Ras homolog family member C (RhoC) gene. RhoC is a member of the Rho GTPase family that regulates the actin cytoskeleton, cell motility, and signal transduction. Overexpression of RhoC is frequently associated with tumor progression, epithelial-mesenchymal transition (EMT), and increased metastatic potential in various malignancies, including bladder cancer. By specifically degrading RhoC mRNA through the RNA interference (RNAi) pathway, RhoC siRNA inhibits the production of the RhoC protein, thereby reducing the invasive and migratory capabilities of cancer cells. In research settings, it is utilized to validate the functional role of RhoC in oncogenic processes and to explore its potential as a therapeutic target for inhibiting metastasis.
- Other names
- siRNA targeting RhoCRhoC small interfering RNARas homolog family member C siRNA
02
Targets
RHOC (Ras homolog family member C)
Beyond the preview
Go deeper on RhoC siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RhoC siRNA.